Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections
Date: April 22, 2019
Issue #:
1570Summary:
Eravacycline (Xerava– Tetraphase), a new synthetic
tetracycline antibiotic, has been approved by the
FDA for IV treatment of complicated intra-abdominal
infections (cIAIs) in adults. Eravacycline is structurally
similar to tigecycline (Tygacil, and generics), a broad-spectrum
tetracycline approved by the FDA for IV
treatment of complicated skin and skin structure
infections, complicated intra-abdominal infections,
and community-acquired pneumonia. A higher rate
of mortality has been reported with use of tigecycline
compared to other antibacterial drugs; it should be
used only when no suitable alternative is available.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Antibacterials Ceftriaxone Doripenem eravacycline Ertapenem Escherichia coli Imipenem/cilastatin Invanz meropenem Merrem methicillin-resistant staphylococcus aureus penicillin Piperacillin/tazobactam Primaxin Pseudomonas aerugi Source Type: research
More News: Ceftriaxone | Drugs & Pharmacology | Gastroenteritis | MRSA | Penicillin | Pneumonia | Rocephin | Skin | Staphylococcus Aureus | Tetracycline